Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Location
53 Frontage Road, Suite 220, Hampton, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
AVANT IMMUNOTHERAPEUTICS INC (to 9/29/2008), T CELL SCIENCES INC (to 8/21/1998)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.06K % +12.2%
Debt-to-equity 5.68 % -24.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.3M shares +40.3%
Common Stock, Shares, Outstanding 66.3M shares +40.3%
Entity Public Float 1.6B USD +23.1%
Common Stock, Value, Issued 66K USD +40.4%
Weighted Average Number of Shares Outstanding, Basic 66K shares +39.7%
Weighted Average Number of Shares Outstanding, Diluted 66K shares +39.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.3M USD +155%
Research and Development Expense 136M USD +39.8%
General and Administrative Expense 35.3M USD +30.7%
Costs and Expenses 184M USD +47.9%
Operating Income (Loss) -176M USD -45%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -112M USD -58.8%
Earnings Per Share, Basic -2.75 USD/shares -14.1%
Earnings Per Share, Diluted -2.75 USD/shares -14.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.7M USD +51.4%
Marketable Securities, Current 760M USD +238%
Assets, Current 812M USD +207%
Property, Plant and Equipment, Net 3.86M USD -1.88%
Operating Lease, Right-of-Use Asset 2.45M USD -24.8%
Intangible Assets, Net (Excluding Goodwill) 27.2M USD 0%
Other Assets, Noncurrent 107K USD 0%
Assets 846M USD +183%
Accounts Payable, Current 3.8M USD +332%
Employee-related Liabilities, Current 9.35M USD +24.2%
Accrued Liabilities, Current 18.6M USD +51.7%
Liabilities, Current 27.7M USD +76.8%
Operating Lease, Liability, Noncurrent 796K USD -53.9%
Other Liabilities, Noncurrent 3.47M USD -21.1%
Liabilities 31.9M USD +46.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.78M USD -14.1%
Retained Earnings (Accumulated Deficit) -1.47B USD -11.4%
Stockholders' Equity Attributable to Parent 814M USD +193%
Liabilities and Equity 846M USD +183%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.6M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 436M USD +62740%
Net Cash Provided by (Used in) Investing Activities -315M USD -700%
Common Stock, Shares Authorized 297M shares 0%
Common Stock, Shares, Issued 66.3M shares +40.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 80.3M USD +225%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.7M USD +51.4%
Deferred Tax Assets, Valuation Allowance 347M USD +11.1%
Deferred Tax Assets, Gross 353M USD +10.9%
Operating Lease, Liability 2.54M USD -37%
Payments to Acquire Property, Plant, and Equipment 344K USD -41.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -151M USD -36%
Lessee, Operating Lease, Liability, to be Paid 2.74M USD -39.8%
Property, Plant and Equipment, Gross 26.4M USD +4.23%
Operating Lease, Liability, Current 1.59M USD +3.86%
Lessee, Operating Lease, Liability, to be Paid, Year Two 949K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.79M USD +0.68%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 195K USD -62.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 896K USD +1127%
Deferred Tax Assets, Operating Loss Carryforwards 198M USD +4.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 775K USD +6.75%
Share-based Payment Arrangement, Expense 29.2M USD +57.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%